BioSpace News Archive

Menarini Silicon Biosystems today announces the launch of the MSBiosuite, a cloud-based data analysis solution that completes the company workflow* for liquid biopsy and formalin-fixed paraffin embedded (FFPE) tissue analysis, and provides a powerful tool to bridge the gap between sequencing data and consolidated results.

Trovagene, Inc. (Nasdaq: TROV), today announced the successful completion of its Phase 1b trial of onvansertib in combination with standard-of-care chemotherapy in acute myeloid leukemia (AML) and initiation of patient enrollment in Phase 2.

USANA, a leader in cellular nutrition, is honored to announce its Coenzyme Q10 (CoQ10) supplement — CoQuinone® 30 — has earned the seal of approval from third-party tester ConsumerLab.com.

Comparative clinical trial met its primary endpoint of change in hemifacial volume at six monthsThe CE Mark provides Lineage, or its authorized agent, the authority to market and distribute Renevia throughout the European Union (EU) and in other countries that recognize the CE Mark.

Overall survival data from CheckMate -227 Part 1 evaluating Opdivo plus low-dose Yervoy in advanced non-small cell lung cancer featured in ESMO Presidential Symposium

OTC Markets Group is the operator of financial markets for 10,000 U.S. and global securities. Ignite upgraded to OTCQX from the Pink® market.

Thursday, September 19, 2019 at 7:00 AM Pacific Time, 10:00 AM Eastern Time

Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine® (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF), for the potential treatment of Stage IIb-IV melanoma.

Tivity Health, Inc. (NASDAQ: TVTY) will present at the 2019 Cantor Global Healthcare Conference to be held October 2-4, 2019 in New York, NY

WuXi Diagnostics announced today the plan to open its first U.S.-based research and diagnostic testing development facility in Rochester, Minnesota to accelerate esoteric diagnostic product development, and bring more personalized and accurate clinical diagnosis services for global patients.